Paydirt
TR
Insider

Timothy Rolph

Chief Scientific Officer

Timothy Rolph (Chief Scientific Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in AKRO. The largest single filing was $527K of AKRO (11,463 sh × $46.01, as filed), executed Oct 7 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$527K
shares × price, as filed
Last traded
Oct 7 2025
Filed Oct 9 2025
Open performance→
Volume by month
$2.2M$1.1M$0Oct 2024Apr 2025Oct 2025Apr 2026Dec 2024 · sells $118KJan 2025 · sells $1.7MFeb 2025 · sells $1.1MMar 2025 · sells $557KApr 2025 · sells $392KMay 2025 · sells $529KJun 2025 · sells $2.2MJul 2025 · sells $542KAug 2025 · sells $616KSep 2025 · sells $551KOct 2025 · sells $527K
Buys $0 Sells $8.8M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names
AKRO AKRO AKRO · 0 buys · 13 sells 13 filings
Recent filings
AKROSALE Akero Therapeutics, Inc. View filing → $135K
3,750 sh × $36.05
Exec Apr 7 2025
Filed Apr 10 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. View filing → $557K
12,500 sh across 2 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.1M
18,750 sh across 2 lots
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.7M
31,250 sh across 3 lots
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $118K
3,800 sh × $31.10
Exec Dec 17 2024
Filed Dec 18 2024 · 5:30 PM ET